![](/img/cover-not-exists.png)
Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects
Axelsen, Lene Nygaard, Poggesi, Italo, Rasschaert, Freya, Perez Ruixo, Juan Jose, Bruderer, ShirinJournal:
British Journal of Clinical Pharmacology
DOI:
10.1111/bcp.14365
Date:
May, 2020
File:
PDF, 1.23 MB
2020